Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 11/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220101 | 0.95 | ACHE (0.51) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL3782856 | 0.90 | SSTR5 (0.62) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL1878170 | 0.87 | SSTR5 (0.51) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL3773308 | 0.87 | SSTR5 (0.64) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL3775155 | 0.84 | APP (0.54) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL3784276 | 0.83 | APP (0.53) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL3781191 | 0.83 | APP (0.53) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL1873548 | 0.81 | SSTR5 (0.54) | ACHEAPPSSTR5HRH1HTR2B | |
| SCHEMBL3776339 | 0.81 | SSTR5 (0.56) | ACHESSTR5HRH1HTR2BBACE1 | |
| SCHEMBL3787693 | 0.81 | SSTR5 (0.58) | ACHESSTR5HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | ACHE 3332/4885APP 2063/4885SSTR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.